12:04:36 EDT Mon 20 May 2024
Enter Symbol
or Name
USA
CA



News for U:RSLS from 2023-05-21 to 2024-05-20 - 24 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-15 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
2024-05-14 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
2024-04-01 16:05U:RSLSNews ReleaseReShape Lifesciences(TM) Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
2024-03-28 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
2024-03-04 08:31U:RSLSNews ReleaseReShape Lifesciences(TM) Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band(TM) 2.0 FLEX
2024-02-22 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Announces First Surgeries Utilizing Next-Generation ‚  Lap-Band ‚ ® 2.0 FLEX
2024-01-24 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Conducts Bariatric Fellows Training for its Lap-Band ‚ ® System, Highlighting the Next-Generation Lap-Band ‚ ® 2.0 FLEX
2023-12-21 07:01U:RSLSNews ReleaseReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex
2023-12-20 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
2023-12-12 16:05U:RSLSNews ReleaseReShape Lifesciences ‚ ® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band ‚ ® 2.0 FLEX
2023-11-21 08:06U:RSLSNews ReleaseReShape Lifesciences ‚ ® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
2023-11-08 16:05U:RSLSNews ReleaseReShape Lifesciences ‚ ® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
2023-11-06 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
2023-09-29 12:30U:RSLSNews ReleaseReShape Lifesciences ‚ ® Announces Pricing of $3.0 Million Public Offering
2023-09-22 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Announces Participation in the LD Micro Main Event XVI
2023-09-21 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Signs Exclusive License Agreement With Biorad Medisys for Obalon ‚ ® Gastric Balloon System
2023-09-19 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Significantly Strengthens Patent Portfolio Related to its Obalon ‚ ® Balloon System
2023-09-14 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation ¢ „ ¢ Device
2023-08-07 16:05U:RSLSNews ReleaseReShape Lifesciences ‚ ® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
2023-08-03 16:05U:RSLSNews ReleaseReShape Lifesciences ‚ ® to Announce Financial Results for the Second Quarter Ended ‚  June 30, 2023 and Provide Corporate Update
2023-06-29 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
2023-06-28 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation ¢ „ ¢ Device at the ASMBS 2023 Annual Meeting
2023-06-26 16:05U:RSLSNews ReleaseReShape Lifesciences ‚ ® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band ‚ ® 2.0
2023-06-14 08:31U:RSLSNews ReleaseReShape Lifesciences ‚ ® to Participate in Investor and Industry Conferences ‚  in June